Skip to main content
ATOSSA THERAPEUTICS, INC. logo

ATOSSA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · ATOS ISIN · US04962H5063 US Manufacturing
Open in API
Filings indexed 622 across all filing types
Latest filing 2015-04-07 Board/Management Inform…
Country US United States of America
Listing US ATOS

About ATOSSA THERAPEUTICS, INC.

https://atossatherapeutics.com/

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative medicines for areas of significant unmet medical need, with a primary focus on oncology. The company is dedicated to addressing the full continuum of breast cancer care. Its lead program is centered on (Z)-endoxifen, a proprietary and potent selective estrogen receptor modulator (SERM). Atossa is advancing (Z)-endoxifen through clinical development for multiple breast cancer indications, including metastatic disease, aiming to provide a therapeutic with a potentially improved efficacy and tolerability profile.

Recent filings

Filing Released Lang Actions
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is used for current reports on significant events. The content specifically reports the departure of a senior officer (Senior Vice President of Sales and Marketing) and the expected effective date. This matches the description of announcements related to changes in the company's board of directors or senior management. The document is not a full report, financial statement, or earnings release, but a regulatory filing about management changes. Therefore, the appropriate classification is Board/Management Information (MANG). The document length is short and focused on management change, confirming this classification with high confidence.
2015-04-07 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 30, 2015, reporting the issuance of a press release announcing fiscal year ended December 31, 2014 financial results and a company update. The text explicitly states that the press release is attached as Exhibit 99.1 and incorporated by reference. The document itself does not contain detailed financial statements or substantive financial data but rather announces the release of such information. The document length is 3153 characters, which is relatively short and consistent with an announcement rather than a full report. According to the 'Menu vs Meal' rule, this is an announcement of a report, not the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for such filings that do not fit other specific categories and are announcements or notices rather than full reports.
2015-03-30 English
FORM 10-K
Annual Report FY 2014
2015-03-30 English
OWNERSHIP DOCUMENT
Director's Dealing
2015-03-19 English
OWNERSHIP DOCUMENT
Director's Dealing
2015-03-19 English
OWNERSHIP DOCUMENT
Director's Dealing
2015-03-19 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.